Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Teaching NeuroImages: Collet-Sicard syndrome and hearing loss with glomus jugulotympanicum.

Ganesh A, Assis Z, Fok D, Cairncross JG, Bal SS, Furtado S.

Neurology. 2019 Oct 1;93(14):e1408-e1409. doi: 10.1212/WNL.0000000000008205. No abstract available.

PMID:
31570645
2.

Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Shen Y, Grisdale CJ, Islam SA, Bose P, Lever J, Zhao EY, Grinshtein N, Ma Y, Mungall AJ, Moore RA, Lun X, Senger DL, Robbins SM, Wang AY, MacIsaac JL, Kobor MS, Luchman HA, Weiss S, Chan JA, Blough MD, Kaplan DR, Cairncross JG, Marra MA, Jones SJM.

Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19098-19108. doi: 10.1073/pnas.1813495116. Epub 2019 Aug 30.

PMID:
31471491
3.

Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors.

Ahmad ST, Rogers AD, Chen MJ, Dixit R, Adnani L, Frankiw LS, Lawn SO, Blough MD, Alshehri M, Wu W, Marra MA, Robbins SM, Cairncross JG, Schuurmans C, Chan JA.

Nat Commun. 2019 May 1;10(1):2000. doi: 10.1038/s41467-019-09949-6.

4.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA, Pedersen H, Chan JA, Shen Y, Marra M, Kaplan DR, Mason W, Goodman LD, Ezhilarasan R, Kaufmann AB, Cabral M, Robbins SM, Senger DL, Cahill DP, Sulman EP, Cairncross JG, Blough MD.

PLoS One. 2018 Aug 28;13(8):e0202860. doi: 10.1371/journal.pone.0202860. eCollection 2018.

5.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P.

Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1. No abstract available.

PMID:
29497819
6.

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M.

Acta Neuropathol. 2018 Mar;135(3):481-484. doi: 10.1007/s00401-018-1808-0. Epub 2018 Jan 25. No abstract available.

PMID:
29372318
7.

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM.

Cancer Res. 2018 May 1;78(9):2290-2304. doi: 10.1158/0008-5472.CAN-17-2926. Epub 2018 Jan 22.

8.

Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.

Opoku-Darko M, Lang ST, Artindale J, Cairncross JG, Sevick RJ, Kelly JJP.

J Neurosurg. 2018 Jul;129(1):19-26. doi: 10.3171/2017.3.JNS17159. Epub 2017 Oct 6.

PMID:
28984519
9.

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.

10.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

11.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.

N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.

12.

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.

Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236. Erratum in: Neuro Oncol. 2017 Feb 1;19(2):e1.

13.

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A.

Acta Neuropathol. 2017 Jan;133(1):1-3. doi: 10.1007/s00401-016-1646-x. No abstract available.

14.

p53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium.

Gorjala P, Cairncross JG, Gary RK.

Cell Prolif. 2016 Dec;49(6):698-709. doi: 10.1111/cpr.12291. Epub 2016 Sep 9.

15.

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.

Neuroimage Clin. 2016 Jun 23;12:180-9. doi: 10.1016/j.nicl.2016.06.018. eCollection 2016.

16.

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.

17.

Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.

Cahill DP, Louis DN, Cairncross JG.

CNS Oncol. 2015;4(5):287-94. doi: 10.2217/cns.15.32. Epub 2015 Nov 6. Review.

18.

Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.

Cusulin C, Chesnelong C, Bose P, Bilenky M, Kopciuk K, Chan JA, Cairncross JG, Jones SJ, Marra MA, Luchman HA, Weiss S.

Stem Cell Reports. 2015 Jul 14;5(1):1-9. doi: 10.1016/j.stemcr.2015.05.010. Epub 2015 Jun 18.

19.

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM.

Cancer Res. 2015 Aug 1;75(15):2999-3009. doi: 10.1158/0008-5472.CAN-15-0840. Epub 2015 Jun 4.

20.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

21.

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.

Chittaranjan S, Chan S, Yang C, Yang KC, Chen V, Moradian A, Firme M, Song J, Go NE, Blough MD, Chan JA, Cairncross JG, Gorski SM, Morin GB, Yip S, Marra MA.

Oncotarget. 2014 Sep 15;5(17):7960-79.

22.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

23.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

24.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr.

J Clin Oncol. 2014 Mar 10;32(8):783-90. doi: 10.1200/JCO.2013.49.3726. Epub 2014 Feb 10.

25.

Lactate dehydrogenase A silencing in IDH mutant gliomas.

Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG.

Neuro Oncol. 2014 May;16(5):686-95. doi: 10.1093/neuonc/not243. Epub 2013 Dec 22.

26.

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.

Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, Anderson C, Blough MD, Cairncross JG, Lafay-Cousin L, Strother D, Hawkins C, Narendran A, Huang A, Chan JA.

Neuro Oncol. 2014 Jan;16(1):62-71. doi: 10.1093/neuonc/not162. Epub 2013 Dec 4.

27.

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

Luchman HA, Chesnelong C, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Aug;15(8):979-80. doi: 10.1093/neuonc/not064. Epub 2013 Jun 11. No abstract available.

28.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

29.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

30.

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.

Blough MD, Al-Najjar M, Chesnelong C, Binding CE, Rogers AD, Luchman HA, Kelly JJ, Fliegel L, Morozova O, Yip S, Marra M, Weiss S, Chan JA, Cairncross JG.

Ann Neurol. 2012 Jun;71(6):845-9. doi: 10.1002/ana.23610.

PMID:
22718548
31.

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31.

32.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

33.

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.

Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA.

J Pathol. 2012 Jan;226(1):7-16. doi: 10.1002/path.2995. Epub 2011 Nov 10.

34.

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R.

Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.

35.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.

Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.

36.

Leptomeningeal disease in oligodendroglial tumors: a population-based study.

Roldán G, Chan J, Eliasziw M, Cairncross JG, Forsyth PA.

J Neurooncol. 2011 Sep;104(3):811-5. doi: 10.1007/s11060-011-0551-3. Epub 2011 Mar 4.

37.

Do epileptic seizures predict outcome in patients with oligodendroglioma?

Mirsattari SM, Chong JJ, Hammond RR, Megyesi JF, Macdonald DR, Lee DH, Cairncross JG.

Epilepsy Res. 2011 Mar;94(1-2):39-44. doi: 10.1016/j.eplepsyres.2011.01.001. Epub 2011 Feb 18.

PMID:
21315558
38.

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG.

J Neurooncol. 2011 Mar;102(1):1-7. doi: 10.1007/s11060-010-0283-9. Epub 2010 Jul 1.

PMID:
20593219
39.

Separating the wheat from the chaff: the search for truly informative biomarkers.

Baehring JM, Cairncross JG.

Neurology. 2010 Jun 8;74(23):1848-9. doi: 10.1212/WNL.0b013e3181e475b7. Epub 2010 May 5. No abstract available.

PMID:
20445147
40.

Sensitivity to temozolomide in brain tumor initiating cells.

Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, Weiss S, Cairncross JG.

Neuro Oncol. 2010 Jul;12(7):756-60. doi: 10.1093/neuonc/noq032. Epub 2010 Apr 13.

41.

Oligodendroglioma cell lines containing t(1;19)(q10;p10).

Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, Perizzolo M, Demetrick DJ, Steele L, Auer RN, Hader WJ, Westgate M, Parney IF, Jenkins R, Cairncross JG, Weiss S.

Neuro Oncol. 2010 Jul;12(7):745-55. doi: 10.1093/neuonc/noq031. Epub 2010 Apr 13.

42.

A multigene predictor of outcome in glioblastoma.

Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K.

Neuro Oncol. 2010 Jan;12(1):49-57. doi: 10.1093/neuonc/nop007. Epub 2009 Oct 20.

43.

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Roldán GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2009 Sep;36(5):617-22.

PMID:
19831132
44.

An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.

Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR.

Neuroimage. 2010 Jan 15;49(2):1398-405. doi: 10.1016/j.neuroimage.2009.09.049. Epub 2009 Sep 28.

PMID:
19796694
45.

Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience.

Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF.

J Neurooncol. 2010 Feb;96(3):403-8. doi: 10.1007/s11060-009-9977-2. Epub 2009 Aug 8.

PMID:
19669097
46.

Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, Forsyth P, Auer RN, Dunn JF, Cairncross JG, Parney IF, Weiss S.

Stem Cells. 2009 Aug;27(8):1722-33. doi: 10.1002/stem.98.

47.

Adult supratentorial low-grade glioma: long-term experience at a single institution.

Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1401-7. doi: 10.1016/j.ijrobp.2009.01.010. Epub 2009 Apr 22.

PMID:
19395201
48.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.

PMID:
19269895
49.

Predicting MGMT methylation status of glioblastomas from MRI texture.

Levner I, Drabycz S, Roldan G, De Robles P, Cairncross JG, Mitchell R.

Med Image Comput Comput Assist Interv. 2009;12(Pt 2):522-30.

PMID:
20426152
50.

Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas.

Mason WP, Cairncross JG.

Neurology. 2008 Jul 29;71(5):365-73. doi: 10.1212/01.wnl.0000319721.98502.1b. Review.

PMID:
18663182

Supplemental Content

Loading ...
Support Center